Nuklex 250 mg capsule number 40
Author Ольга Кияница
|Amount in a package||40|
|Manufacturer||Pharma Start LLC (Ukraine, Kiev)|
|The main medicament||-|
Complex therapy of viral hepatitis often involves the use of Nuklex , a drug that inhibits viral activity, blocking the replication of viruses and their penetration into the cells of the body. Due to this property in the instruction Nukleks it is indicated that the agent is used for the treatment and prevention of acute respiratory diseases.
NUCLEX instruction manual
Composition and form of release:
caps. 250 mg blister, No. 10, No. 20, No. 40
caps. 250 mg container, No. 80
Ribonucleic acid 250 mg
Nuklex has a specific antiviral activity. The antiviral action is based on mechanisms of influence on the conformation of surface antigens and receptors of viruses. Inhibits hemagglutination and neuraminidase activity of influenza and parainfluenza viruses, blocking the penetration of viruses into the cell and their replication, provides a preventive and curative antiviral effect. Suppresses the growth of concentration of other viruses that cause ARVI.
Stimulates the migration of stem cells in the bone marrow, restores differentiation, quantitative and qualitative composition of bone marrow cells and peripheral blood. Normalizes cellular immunity, increasing the migration and cooperation of T and B lymphocytes and phagocytic activity of macrophages, enhancing the activity of factors of nonspecific resistance. It has anti-inflammatory, immunomodulating, antioxidant, organoprotective, anti-ischemic and hematopoietic activity and suppresses increased platelet aggregation.
Pharmacotherapeutic effects of the drug are based on the following mechanisms: stimulation of the processes of cellular metabolism, enhancement of the biosynthesis of endogenous nucleic acids, specific enzymes and proteins, enhancement of the mitotic activity of bone marrow cells, acceleration of regeneration processes, increase in energy supply of cells by stimulating the synthesis of macroergic compounds such as ATP.
Anti-inflammatory activity is provided by regulation of adenosine Ade1 receptor, normalization of NO-synthetase activity, inhibition of oxidative processes in cell membranes, stabilization of cell membranes and optimization of oxidation-reduction processes in tissues.
Specific antiviral activity is provided by changing the conformation of neuraminidase and hemagglutinin receptors of influenza and parainfluenza viruses, and non-specific by increasing the production of interferon in vivo and stimulating nonspecific antiviral protection.
A specific cardioprotective effect is provided by a positive effect on the dynamics of formation of the myocardium necrosis zone and a decrease in the final mass of the necrosis zone, an increase in the left ventricular ejection fraction.
Regulation of the hormonal system is accompanied by activation of the pituitary-adrenal system with an increase in the level of endogenous GCS. The drug optimizes adrenergic and cholinergic regulation of heart activity, coronary and systemic blood flow with the participation of sympathetic and parasympathetic nervous systems. Nukle relaxes the coronary vessels on the background of their adrenaline reduction and reduces blood pressure.
Nephroprotective properties are provided by increasing the global index of kidney function - the glomerular filtration rate.
Antiviral efficacy. During Phase II clinical trials, patients received Nulex during the entire treatment period after the onset of symptoms of influenza or ARVI. The treatment significantly reduced the duration of clinically relevant complaints and objective symptoms by 1-3 days. The effectiveness of therapy in patients with a verified diagnosis of influenza or ARI who were taking Nuklex was almost 30% higher than in the control group. Nukle significantly reduced the incidence of complications of influenza and ARVI in patients who need antibiotic therapy (bronchitis, pneumonia, sinusitis, otitis media). Data from studies in patients with concomitant diseases of the cardiovascular and / or respiratory systems show that Nuclex was accompanied by a clinically significant decrease in the severity of the symptoms of the concomitant disease of these risk groups.
as an antiviral drug for the prevention and treatment of ARVI and influenza. In the complex therapy of chronic viral hepatitis, urogenital herpes. As a cardioprotective agent in the complex therapy of ischemic heart disease, acute myocardial infarction, ischemic cardiomyopathy.
as an antiviral drug is administered orally to adults, 500 mg 2-3 times a day, before or after meals for 5-7 days, and then 250 mg twice a day for 7-14 days. For the purpose of prophylaxis orally, 250 mg before or after meals during the period of the acute respiratory viral infection and influenza.
As a cardioprotective drug is administered orally 500 mg 2-3 times daily after meals. The course of treatment is 10-15 days. Prophylactically, orally - 50 mg after meals for 3-4 months 2 times a year.
individual intolerance of the drug components, hemoblastosis (leukemia, malignant lymphoma). Gout.
from the digestive tract: with oral administration on an empty stomach, pain in the epigastrium is possible.
From the side of metabolism: increased levels of uric acid in the blood plasma.
There may be hypersensitivity, requiring hyposensitizing therapy. Treatment is carried out under the control of the immune status.
treatment is carried out under the control of the immune status and the level of uric acid.
Use during pregnancy and lactation.
There is insufficient clinical experience of the drug during pregnancy and lactation, so the drug is not used in these patients.
To date, there is not enough experience in Nuclex in children, so do not prescribe a drug for this age group of patients.
The ability to influence the reaction rate when driving vehicles or working with other mechanisms.
Nuklex does not affect the reaction rate when driving vehicles or working with other mechanisms.
with the simultaneous use of Nucleks with antibiotics and vitamins in complex therapy, the therapeutic effectiveness of treatment is greatly enhanced. When used simultaneously with antiplatelet agents and anticoagulants, in connection with an increased risk of bleeding, it is necessary to monitor blood coagulation. If it is necessary to appoint a patient with a high level of uric acid in a history, the drug is recommended to be used simultaneously with allopurinol.
no symptoms of overdose.
at a temperature of no higher than 25 ° C.